3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Fallopian Tube Neoplasms
7
Ovarian Neoplasms
6
Colorectal Neoplasms
5
Urinary Bladder Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Carcinoma, Hepatocellular
4
Lymphoma, Large B-Cell, Diffuse
3
Glioblastoma
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Brain Neoplasms
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Lymphoid Interstitial Pneumonia
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma
2
Burkitt Lymphoma
2
Brenner Tumor
2
Breast Neoplasms
2
Interventions
Ipilimumab
2
spartalizumab
1
pembrolizumab
1
eribulin
1
durvalumab
1
balstilimab
1
Specimen Handling
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Disulfides
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Hemangiosarcoma
×
Disulfides
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled